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Many studies have illustrated that the production of
reactive oxygen species (ROS) is important for optimal
tyrosine phosphorylation and signaling in response to
diverse stimuli. Protein-tyrosine phosphatases (PTPs),
which are important regulators of signal transduction,
are exquisitely sensitive to inhibition after generation
of ROS, and reversible oxidation is becoming recognized
as a general physiological mechanism for regulation of
PTP function. Thus, production of ROS facilitates a ty-
rosine phosphorylation-dependent cellular signaling re-
sponse by transiently inactivating those PTPs that nor-
mally suppress the signal. In this study, we have
explored the importance of reversible PTP oxidation in
the signaling response to insulin. Using a modified in-
gel PTP assay, we show that stimulation of cells with
insulin resulted in the rapid and transient oxidation
and inhibition of two distinct PTPs, which we have iden-
tified as PTP1B and TC45, the 45-kDa spliced variant of
the T cell protein-tyrosine phosphatase. We investigated
further the role of TC45 as a regulator of insulin signal-
ing by combining RNA interference and the use of sub-
strate-trapping mutants. We have shown that TC45 is an
inhibitor of insulin signaling, recognizing the -subunit
of the insulin receptor as a substrate. The data also
suggest that this strategy, using ligand-induced oxida-
tion to tag specific PTPs and using interference RNA
and substrate-trapping mutants to illustrate their role
as regulators of particular signal transduction path-
ways, may be applied broadly across the PTP family to
explore function.
The reversible phosphorylation of tyrosyl residues in pro-
teins, catalyzed by the coordinated actions of protein tyrosine
kinases and protein-tyrosine phosphatases (PTPs),1 is of para-
mount importance to the control of such fundamental physio-
logical functions as cell proliferation, differentiation, survival,
metabolism, and motility (1, 2). The phosphorylation of a target
protein alters its function, including changes in enzymatic ac-
tivity or its ability to associate with other proteins. In response
to a stimulus, such as a growth factor or hormone, multiple
phosphorylation and dephosphorylation reactions are coordi-
nated in signal transduction cascades that culminate in the
physiological response (3, 4). A characterization of the enzymes
responsible for the regulation of protein tyrosine phosphoryla-
tion in vivo will be essential for an understanding of the control
of signal transduction under normal and pathophysiological
conditions and would be expected to identify important new
targets for therapeutic intervention in human disease. We are
focusing on this process from the perspective of the PTP family
of enzymes.
A substantial body of information has been accumulated to
describe the role of protein tyrosine kinases in the regulation of
signal transduction. In contrast, we are only now beginning to
appreciate in mechanistic detail the role of some members of
the PTP family in fine-tuning the signaling response to extra-
cellular stimuli. Analysis of the human genome sequence re-
vealed the existence of 38 PTP genes in humans (5, 6). These
PTPs compose receptor-like proteins, which have the potential
to regulate signaling directly through ligand-controlled protein
dephosphorylation, as well as nontransmembrane, cytoplasmic
enzymes. In addition, there are 60 dual-specificity phos-
phatases, which are members of the PTP family that recognize
Ser/Thr and Tyr residues in proteins (3).2 This structural di-
versity in the family is indicative of their functional importance
in the control of cell signaling, and it is now apparent that the
PTPs have the potential to display exquisite substrate, and
functional, specificity in vivo. The substrate specificity of PTPs
is determined both by targeting the enzymes to defined subcel-
lular locations, via their noncatalytic domains (7), and through
structural features intrinsic to their catalytic domains (8).
Moreover, the activity of PTPs themselves is regulated through
post-translational modifications in response to extracellular
stimuli. The combination of these mechanisms and the control
of protein tyrosine kinases govern the tyrosine phosphorylation
of PTP substrates in a spatial and time-dependent manner.
Recently, a novel tier of control of tyrosine phosphorylation-
dependent signaling, and PTP function in particular, has been
revealed. The production of reactive oxygen species (ROS) in
response to a diverse array of physiological stimuli is currently
viewed as an important mechanism for fine-tuning tyrosine
phosphorylation-dependent signaling (9–12). Attention has
been drawn to the PTPs as targets of ROS because the signa-
ture motif of this family, [I/V]HCXXGXXR[S/T], contains an
invariant Cys residue that, because of the unique environment
of the PTP active site, is characterized by an extremely low pKa
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(13, 14). The low pKa promotes the function of this Cys residue
as a nucleophile in catalysis but renders it highly susceptible to
oxidation with concomitant inhibition of PTP activity (15–17).
It is now known that multiple PTPs are transiently oxidized by
H2O2 (18–20) and also in response to certain cellular stimuli
(17, 21–24), illustrating that this mode of regulation may apply
broadly across the enzyme family (25).
In the present study, we have investigated the importance of
ROS production and concomitant PTP inhibition in the context
of insulin-mediated signal transduction. We demonstrate that
ectopic expression of catalase impaired both insulin signaling
and tyrosine phosphorylation of the -subunit of the insulin
receptor. Using a modified in-gel PTP assay (19), we observed
that two PTPs were rapidly and transiently oxidized in re-
sponse to insulin. We identified these PTPs as PTP1B and the
45-kDa spliced variant of T-cell PTP (TC-PTP, TC45). We ex-
plored further the role of TC45 in regulating insulin-stimulated
signal transduction using a combination of RNA interference
and substrate-trapping mutant forms of the enzyme. We have
demonstrated that suppression of endogenous TC45 expression
via RNA interference enhanced phosphorylation of the -sub-
unit of the insulin receptor and signaling in response to insulin,
consistent with removal of a signaling component that exerts
an inhibitory constraint on the system. Consistent with this,
we observed that substrate-trapping mutant forms of TC45
formed a complex with the -subunit of the insulin receptor.
Our study not only demonstrates that TC45 may function as a
regulator of insulin signaling but also illustrates the potential
for applying this strategy to the identification and character-
ization of PTPs that control a broad array of signal transduc-
tion pathways.
MATERIALS AND METHODS
Preparation of Small Interfering RNA (siRNA) Oligonucleotides—To
design specific siRNA duplexes, we scanned through the open reading
frame of TC45 mRNA and selected sequences of 5-AA(N19)-3 (N  any
nucleotide) for further characterization. Two oligonucleotides, 5-AAC-
AGAUACAGAGAUGUAAGC-3 (termed TCPTP1) and 5-AGCCCAU-
AUGAUCACAGUCG-3 (TCPTP2), were chosen. These sequences were
submitted to a BLAST search against human, rat, and mouse genome
databases to ensure specificity for TC-PTP. The 21-nucleotide siRNA
duplexes were purchased from Dharmacon Research in a deprotected
and desalted form. At 50–100 nM, both siRNA oligonucleotides sup-
pressed expression of endogenous TC45 in HepG2 cells (human hepa-
tocellular carcinoma) and Rat-1 fibroblasts. Data are presented mostly
from the use of the TCPTP1 siRNA, but were confirmed with the
TCPTP2 siRNA, to illustrate that the observed effects were target-
specific rather than siRNA-specific.
Cell Culture and Transient Transfection with Plasmids and siRNA—
Rat-1 and HepG2 cells were routinely maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bovine serum, 1%
glutamine, 100 units/ml of penicillin, and 100 g/ml of streptomycin.
For stimulation with insulin, cells were plated in medium containing
10% fetal bovine serum for 48 h and then were serum-starved for 16 h
before treatment. For transient transfection, cells were plated in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum for 16 h and then in OptiMEM (Invitrogen) without serum, after
which the plasmid (5 g/dish for Rat-1, 30 g/dish for HepG2) was
introduced by LipofectAMINE and PLUS reagents (Invitrogen), accord-
ing to the manufacturer’s recommendations. For RNA interference
(RNAi) experiments, cells were plated as above, and the TC-PTP siRNA
duplexes were introduced by Oligofectamine (Invitrogen) according to
the guidelines provided by Dharmacon Research Inc.
Substrate-trapping, Immunoprecipitation, and Immunoblotting—
For substrate-trapping experiments, HepG2 cells ectopically expressing
wild-type or substrate-trapping mutant (DA) forms of PTPs were rinsed
with ice-cold PBS and then lysed in trapping lysis buffer (20 mM Tris
(pH7.4), 1% Nonidet P-40, 150 mM NaCl, 10% glycerol, 10 mM iodoacetic
acid (IAA), and protease inhibitors (25 g/ml of aprotinin and leupep-
tin)). For immunoprecipitation, cells were lysed in lysis buffer contain-
ing 20 mM Hepes (pH 7.5), 1% Nonidet P-40, 150 mM NaCl, 10%
glycerol, 200 M Na3VO4 and protease inhibitors (25 g/ml of aprotinin
and leupeptin). Lysate (1 mg for substrate-trapping experiments, 400
g for immunoprecipitation, or as indicated in the figure legend for the
individual experiment) was incubated with 5 g of antibody conjugated
to protein A/G-Sepharose (Amersham Biosciences) for 2 h at 4 °C. For
immunoblotting, aliquots of total lysates (30 g/sample) or immunopre-
cipitates were subjected to SDS-PAGE and transferred to nitrocellulose
filters, which were incubated with appropriate primary and secondary
antibodies, and the specific signals were visualized by the ECL detec-
tion system (Amersham Biosciences).
Modified In-gel PTP Activity Assay—After stimulation, cells were
lysed under anaerobic conditions in an argon chamber. The lysis buffer
comprised 25 mM CH3COONa, 1% Nonidet P-40, 150 mM NaCl, 10%
glycerol, pH 5.5, which had been degassed prior to addition of catalase
and superoxide dismutase (both 100 g/ml), protease inhibitors, and 10
mM IAA. Lysates (25 g) were subjected to an “in-gel” phosphatase
assay (26) using SDS-PAGE gels containing 32P-labeled reduced, car-
boxamidomethylated and maleylated lysozyme (RCML) as substrate
(1.5  106 cpm/20 ml of gel solution, 2 M p-Tyr). The details of this
method are described by Meng and Tonks (27).
RESULTS
Hydrogen Peroxide Mediates Insulin Signaling in Rat-1
Cells—We tested the hypothesis that production of ROS is
important for an optimal signal transduction response to insu-
lin. Rat-1 cells were preloaded with a ROS indicator,
H2DCFDA, which, upon encountering ROS, such as H2O2, in
cells is oxidized, thereby converting it to the fluorescent deriv-
ative 2,7-dichlorofluorescein (DCF). The data shown in Fig.
1A illustrate that treatment of Rat-1 cells with insulin trig-
gered production of ROS, as observed by the increased fluores-
cence resulting from the generation of DCF. Furthermore, ec-
topic expression of catalase, to suppress the production of
intracellular H2O2, abrogated the generation of DCF fluores-
cence in response to insulin. This observation indicates that
H2O2 is a major constituent of the ROS produced in the cells in
response to insulin stimulation. In conjunction with this ap-
proach, we assessed the importance of insulin-mediated ROS
production on phosphorylation of tyrosyl residues in the acti-
vation loop of the -subunit of the insulin receptor and down-
stream signaling to the protein kinase PKB/AKT. Transfec-
tants expressing different levels of exogenous catalase (Fig. 1B)
were exposed to insulin for 10 min, after which the extent
of phosphorylation of the tandem tyrosine residues
(pYpY1162/1163) in the activation loop of the insulin receptor
-subunit and the phosphorylation of PKB/AKT were analyzed
by immunoblotting with appropriate phospho-specific antibod-
ies. Both the tyrosine phosphorylation of the insulin receptor
and the activation of PKB/AKT were inhibited in the presence
of exogenous catalase in a dose-dependent fashion (Fig. 1B).
These data suggest that H2O2 production in response to insulin
is important for an optimal signaling response to the hormone.
Insulin Stimulation Leads to Reversible Oxidation and Inac-
tivation of PTP1B and TC45—We examined the effect of insu-
lin-induced H2O2 production on PTP oxidation using a modified
in-gel PTP assay (19, 27). Control and insulin-stimulated Rat-1
cells were lysed under anaerobic conditions in the presence of
IAA, which led to irreversible alkylation of the catalytic Cys
residue of any PTPs in the lysate that were in the reduced,
active form. In contrast, any PTPs that had been oxidized in
response to insulin-induced production of H2O2 were protected
from alkylation by IAA. In the assay, an aliquot of lysate was
subjected to SDS-PAGE in a gel that was cast to contain a
radioactively labeled substrate, and the proteins in the gel
were sequentially denatured and then renatured in the pres-
ence of reducing agent. Under these conditions, only the activ-
ity of those PTPs that were susceptible to insulin-induced oxi-
dation was recovered and visualized by the appearance of a
clear, white area of dephosphorylation, surrounding the posi-
tion of the PTP in the gel, on the black background of radioac-
tively labeled substrate. We observed that two PTPs, of Mr
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50,000 and 45,000, were rapidly and reversibly oxidized, reach-
ing a maximum at 5–10 min, after insulin stimulation (Fig. 2).
Ectopic expression of catalase, which impaired the signaling
response to insulin, also inhibited the oxidation of these PTPs
(Fig. 2). On the basis of the apparent Mr of the 50K and 45K
PTPs, we predicted their identities as PTP1B and TC45, the
45-kDa splice variant of TC-PTP, respectively. This was con-
firmed by immunodepletion and immunoblot analyses. The
anti-PTP1B antibody FG6 immunoprecipitated the 50-kDa
PTP from cell lysates, leaving the 45-kDa PTP in the immuno-
supernatant (Fig. 3A). Conversely, antibodies to TC45 depleted
the 45-kDa PTP specifically, leaving the 50-kDa enzyme in the
supernatant (Fig. 3B).
Ablation of Endogenous TC45 Expression by RNAi Results in
Enhanced PKB/AKT Activation in Response to Insulin—A sub-
stantial body of literature already links PTP1B to the regula-
tion of signaling in response to insulin. To explore the potential
regulatory role of TC45 in insulin signaling, we examined the
phosphorylation status of PKB/AKT, which is a critical effector
in the phosphatidylinositol 3-kinase pathway that mediates
various intracellular responses to insulin (28), following abla-
tion of the PTP by RNAi. Transfection of Rat-1 cells with siRNA
specific for TC45 led to ablation of expression of the endogenous
enzyme (Fig. 4). In contrast, we detected no effect on the level
of expression of PTP1B, chosen as a control because it is the
closest homolog of TC-PTP. Furthermore, there was no effect
on the level of PKB/AKT. Rat-1 transfectants were stimulated
with insulin, and the phosphorylation of PKB/AKT was moni-
tored over the indicated time course by immunoblotting with
phospho-PKB/AKT-specific antibodies. We observed that the
ablation of TC45 by RNA interference enhanced and prolonged
the activation of PKB/AKT in response to insulin, compared
with the signaling response in the control cells (Fig. 4).
To explore additional cell models that are used more exten-
sively to study insulin signaling, we chose the human hepa-
toma cell line HepG2 (29). HepG2 cells expressed higher levels
of insulin receptor than Rat-1 cells and displayed a more robust
response to insulin stimulation, in terms of overall tyrosine
phosphorylation of the insulin receptor -subunit and auto-
phosphorylation of the activation loop tyrosines 1162 and 1163
(Fig. 5A). Furthermore, and of particular importance to our
study, it has been shown that treatment with insulin triggers
H2O2 production in HepG2 cells (21). As shown in Fig. 5B, upon
transfection of HepG2 cells with siRNA specific for TC-PTP, we
FIG. 1. Hydrogen peroxide is an im-
portant mediator of insulin signal-
ing. A, serum-starved Rat-1 cells, either
control (5 g of vector DNA) or ectopically
expressing human catalase (5 g of plas-
mid DNA, a gift from Dr. Toren Finkle,
National Institutes of Health, Bethesda,
MD), were preloaded with 5 M 5-(and-6)-
chloromethyl-2,7-dichlorodihydrofluo-
rescein diacetate (CM-H2DCFDA) (Molec-
ular Probes) in the dark for 15 min and
then exposed to insulin (50 nM). Images of
ROS-induced DCF fluorescence were cap-
tured by fluorescence microscopy by using
a Zeiss Axiovert 405M inverted micro-
scope equipped with a fluorescence at-
tachment and digital camera and are
shown at 50. The data are representa-
tive of three independent experiments. B,
Rat-1 cells were transiently transfected
with different quantities of plasmid en-
coding human catalase. The empty vector
(Vect) was included together with the cat-
alase expression plasmid (Cat) to normal-
ize the total amount of DNA added to
cells. Two days after transfection, cells
were serum-deprived and then stimu-
lated with 50 nM insulin (INS) for 10 min.
The cells were lysed, and catalase expres-
sion was verified by immunoblotting with
anti-catalase antibody (Calbiochem) (top
panel). The insulin receptor -subunit
was immunoprecipitated (IP) with anti-
body 29B4 (Santa Cruz) and then immu-
noblotted with anti-pYpY1162/1163 anti-
body (Biosource) to examine the
phosphorylation status and subsequently
with the anti--subunit antibody clone
C-19 (Santa Cruz) as a loading control
(middle panel). An aliquot of lysate (30
g) was subjected to immunoblotting with
anti-phospho-PKB antibody (Cell Signal-
ing). The same filter was then stripped
and reprobed with anti-PKB antibody
(Cell Signaling) as a loading control (bot-
tom panel).
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observed ablation of expression of the endogenous enzyme. As
in Rat-1 cells, we detected no effect on the level of expression of
PTP1B, the closest homolog of TC-PTP, or PKB/AKT. A com-
parison of insulin-induced phosphorylation of PKB/AKT in con-
trol and siRNA-transfected HepG2 cells illustrated that deple-
tion of TC45 enhanced both the intensity and duration of the
signaling response. It is important to note that these effects
were observed with two distinct TC-PTP-directed siRNA oligo-
nucleotides (Fig. 5C).
PKB/AKT is phosphorylated and activated in response to
FIG. 2. Insulin induced the transient
oxidation of two PTPs in Rat-1 cells.
Serum-starved Rat-1 cells, either control (5
g of vector DNA) or ectopically expressing
catalase (5 g of plasmid DNA), were ex-
posed to 50 nM insulin for the indicated
times. Lysates were prepared under anaer-
obic conditions in the presence of 10 mM
IAA and then subjected to in-gel PTP as-
says (upper panel). The arrowheads indi-
cate the 50-kDa and 45-kDa PTPs that
were transiently oxidized in response to
insulin. The lower panels are immunoblots
to illustrate the expression of catalase and
tubulin; the latter were included as loading
controls.
FIG. 3. Insulin induced the transient oxidation of PTP1B and TC45. A and B, total lysate (400 g) was incubated with either normal IgG
(C), anti-PTP1B antibody (FG6 in A), or anti-TC45 antibody (1910H (59) in B) coupled to protein G-Sepharose beads. After immunoprecipitation,
the immunocomplexes and supernatants (Sup) were collected and then subjected to in-gel PTP assays. A, immunodepletion of the Mr 50K PTP from
the lysate with anti-PTP1B antibody. B, immunodepletion of the Mr 45K PTP with antibody specific for TC45. The lane marked Lys represents cell
lysate before immunodepletion. The lower panels illustrate immunoblots of total lysate and the supernatants after immunodepletion, using either
anti-PTP1B (A) or anti-TC45 (B) antibody (Ab). The data show complete depletion of the PTP protein after immunoprecipitation (IP) with the
specific antibody. The same blot was subsequently reprobed with anti-SHP-2 antibody (C-18, Santa Cruz) to ensure equal loading.
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multiple stimuli (30). Therefore, we compared the effects of
ablation of TC-PTP expression on activation of PKB/AKT in
response to different stimuli to provide insights into the poten-
tial for selectivity in the effects of the phosphatase on signaling
events. Both Rat-1 control cells and siRNA transfectants were
stimulated with platelet-derived growth factor BB (PDGF-BB).
The tyrosine phosphorylation of the -form of PDGF receptor
(PDGFR) was analyzed by immunoblotting. As shown in Fig. 6,
the ablation of endogenous TC45 expression via RNAi did not
alter PDGF-induced autophosphorylation of PDGFR-. Fur-
thermore, suppression of TC45, which augmented insulin-in-
duced activation of PKB/AKT (Figs. 4 and 5), did not affect the
activation of PKB/AKT in response to PDGF stimulation (Fig.
6). These results reveal specificity in the signaling function of
TC-PTP and illustrate that it did not play a regulatory role in
PKB/AKT signaling induced by PDGF.
TC45 Recognizes Tyrosine Phosphorylated Insulin Receptor-
-Subunit as a Substrate in Vivo—To address the mechanism
by which TC45 inhibited insulin-mediated signaling, we used a
substrate-trapping mutant form of the enzyme. We had shown
previously that in any PTP mutation of the invariant aspartate
residue, which functions as a general acid in catalysis, to ala-
nine creates a substrate-trapping mutant that can be used to
identify physiological substrates of the enzyme (31). We ex-
pressed wild-type and substrate-trapping mutant (DA) forms of
TC45 and PTP1B in HepG2 cells and tested whether a complex
was detected between the PTP and the insulin receptor -sub-
unit. As expected, an association between the DA mutant, but
not the wild-type form of PTP1B, and the -subunit was ob-
served in immunoprecipitates of the PTP from insulin-treated
HepG2 cells (Fig. 7A), consistent with other reports (32). Fur-
thermore, we also observed association between the DA mutant
form of TC45 and the insulin receptor -subunit (Fig. 7A).
These data show that TC45 can recognize the insulin receptor
directly as a substrate and suggest that it may function in a
coordinated manner with PTP1B to regulate phosphorylation
of the insulin receptor.
We pursued this matter further by direct examination of the
phosphorylation status of the insulin receptor -subunit in
TC45 siRNA transfected HepG2 cells, including the use of
antibodies to particular phosphorylation sites in the receptor.
We observed, by immunoblotting with antibodies to phospho-
tyrosine, that the overall tyrosine phosphorylation of the -sub-
unit was enhanced and remained elevated for a prolonged
period after ablation of TC45 by RNAi (Fig. 7B). Interestingly,
at these early time points after insulin stimulation, there was
little discernible effect of TC45 siRNA on autophosphorylation
of the activation loop, whereas the phosphorylation of Tyr-972
was enhanced in the absence of the PTP (Fig. 7B). Tyr-972 of
the -subunit, which is located in the juxtamembrane segment
of the insulin receptor, is important for the recruitment of
IRS-1 and Shc and for the activation of phosphatidylinositol
3-kinase (33). Thus, its dephosphorylation by TC45 would be
consistent with a mechanism by which the PTP may influence
insulin-induced signaling via PKB/AKT. The data also suggest
that TC45 influences the phosphorylation status of the insulin
receptor -subunit at later points in the time course of insulin
stimulation, although the identity of the phosphorylation sites
remains to be determined. Interestingly, there are additional
sites of tyrosine phosphorylation in the C-terminal portion of
the insulin receptor that have been implicated in the regulation
of receptor function (34). Although these sites may also be
substrates for TC-PTP, generation of appropriate phospho-spe-
cific antibodies will be required to address this issue further.
Nonetheless, these observations highlight the important point
that PTPs not only have the potential to display specificity for
particular substrate proteins but also to show a preference for
particular sites within those proteins.
DISCUSSION
Although initially viewed as a harmful by-product of life in
an aerobic environment, it is now apparent that there are
beneficial effects of the controlled production of ROS in the
regulation of cellular homeostasis. The production of ROS by
phagocytic leukocytes plays a critical role in the innate im-
mune response to pathogens (12). Detailed analysis of the
multi-component NADPH oxidase in leukocytes has illus-
trated how the production of ROS may be tightly regulated.
The core of the NADPH oxidase enzymes is a two-subunit
flavocytochrome b558 (cyt b) comprising gp91
phox (Nox 2) and
p22phox, which catalyzes the single-electron reduction of ox-
ygen from NADPH as an electron donor, to generate super-
oxide, which is then converted to H2O2, either spontaneously
or by the action of superoxide dismutase (11, 12). The activity
of the Nox enzyme in cell membranes is tightly controlled by
additional, cytosolic regulatory proteins. The small GTPase
Rac, an activator protein p67phox and an organizer protein
p47phox, together with an additional subunit p40phox, form a
complex with cyt b after cell stimulation that induces the
reduction of molecular oxygen (12, 35). This process is regu-
lated by phosphorylation of p47phox, which together with Rac,
links signaling events to the generation of ROS (36). Impor-
tantly, a family of Nox homologs has now been identified in
nonphagocytic cells. The production of ROS by these enzymes
and the resulting post-translational modification of proteins
by reversible oxidation have been implicated in the regula-
FIG. 4. Ablation of TC45 by RNAi enhanced insulin-induced activation of PKB in Rat-1 cells. Rat-1 cells were left untransfected
(Control) or transfected (siRNA) with 100 nM siRNA oligonucleotide to TC45 (TCPTP1). Two days after transfection, cells were deprived of serum
for 16 h and then stimulated with 10 nM insulin for the indicated times. Total lysates (30 g) were immunoblotted with antibodies to phospho-PKB,
PKB, TC45 (1910H), or PTP1B (FG6) (left panel). The right panel illustrates densitometric analyses of the gel images to show the ratio of
phosphorylated PKB to total PKB (A.U., arbitrary unit). Similar results were observed in two independent experiments.
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tion of tyrosine phosphorylation-dependent signaling path-
ways initiated by a wide array of stimuli, including hor-
mones, growth factors, cytokines, and cellular stresses (12).
The architecture of the active site of members of the PTP
family and the critical role of the invariant, low-pKa, catalytic
cysteine residue highlight the potential of the PTPs as targets
for such a regulatory mechanism (3, 37). Work from several
laboratories has now established that multiple members of the
PTP family are susceptible to reversible oxidation, both in vitro
and in cell culture (9, 25). In the classical PTPs, such as PTP1B,
oxidation of this cysteine to sulfenic acid, with subsequent
conversion into a sulfenamide species (38), abrogates the nu-
cleophilic properties of this residue, thereby inhibiting PTP
activity. This is a reversible modification. Conversion of the
oxidized sulfenic acid to the sulfenamide form of the active-site
cysteine induces profound conformational changes at the PTP
active site, which both disrupt the interaction with substrate
and expose the oxidized cysteine to the environment of the cell.
This serves the dual purpose of preventing irreversible oxida-
tion to higher oxidized forms of the active site cysteine (sulfinic
and sulfonic acid) and facilitating the reduction of the sulfen-
amide to restore the active form of the PTP (38). The dual
FIG. 5. Ablation of TC45 enhanced insulin-induced activation of PKB in HepG2 cells. A, serum-deprived Rat-1 and HepG2 cells were
exposed to 10 or 50 nM insulin for 5 min and lysed. The insulin receptor was immunoprecipitated with anti--subunit antibody 29B4 and then
immunoblotted with anti-phosphotyrosine, anti-pYpY1162/1162-IR-, and anti-IR- (C-19) antibodies. B, HepG2 cells were left untransfected
(Control) or transfected (siRNA) with 100 nM siRNA oligonucleotide to TC45 (TCPTP1). Two days after transfection, cells were serum-starved for
16 h and then stimulated with 10 nM insulin for the indicated times. Total lysates (30 g) were immunoblotted with anti-phospho-PKB, anti-PKB,
anti-TC45, and anti-PTP1B antibodies (left panel). The right panel illustrates a densitometric analysis of the gel image to show the ratio of
phosphorylated PKB relative to total PKB (A.U., arbitrary unit). Similar results were observed in three independent experiments. C, the
experiment described in B was repeated using two distinct TC45 siRNAs.
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specificity phosphatases cdc25C (20) and PTEN (18), as well as
the low Mr PTP (22), are also sensitive to oxidation. Unlike the
classical PTPs, these enzymes contain a second cysteine resi-
due within the active site. After oxidation of the nucleophilic
cysteine within the signature motif, a disulfide bond is formed
with the vicinal cysteine within the active site, which protects
the enzymes from the irreversible inactivation that would re-
sult from the formation of higher oxidized species. The SOS
bond can be readily reduced, for example mediated by thiore-
doxin in the case of PTEN (18), which ensures the transient
nature of the modification and returns the enzymes to their
active form. Interestingly, oxidation may also underlie a mech-
anism for regulation of receptor PTPs. In RPTP, the cysteine
of the signature motif from the second, membrane-distal PTP
domain (RPTP-D2) is more susceptible to oxidation than the
membrane-proximal catalytic domain (39). Oxidation of
RPTP-D2 inside the cell leads to a change in the conformation
of the extracellular segment of RPTP (40), suggesting that the
membrane-distal PTP domain may serve as an oxygen sensor
and may underlie inside-out signaling through RPTP.
With the completion of the sequence of the human genome,
we are now in a position to define the composition and diversity
within families of enzymes. In the case of the PTPs, we have
identified 100 PTP genes in humans (3, 6). This represents
the minimal level of complexity in the family, with additional
diversity introduced through use of alternative promoters, al-
ternative mRNA splicing, and post-translational modification.
Broadly speaking, PTPs are known to play either inhibitory or
permissive roles in regulating the physiological response to
particular ligands. For example, SHP-2 promotes signaling
through the epidermal growth factor receptor but down-regu-
lates signaling in response to PDGF (41). Nevertheless, the
majority of the PTPs are known primarily by their sequence,
there being little information on their physiological function.
The current challenge is to develop methods for assigning func-
tion to each of the PTPs. The generation of substrate-trapping
mutant PTPs allows exploration of the physiological substrate
specificity of these enzymes, which provides insights into func-
tion (31). The limitation is the requirement first to identify an
appropriate system in which to express these mutant PTPs.
Ideally, one would like to start with a particular signaling
pathway and find a method to tag and identify the critical PTPs
that are the regulators of that pathway. The reversible oxida-
tion of PTPs that is induced by various physiological stimuli
offers such a strategy. We formulated the hypothesis that stim-
ulus-induced oxidation could be used as a means of “tagging”
the specific PTPs that are integral to the regulation of signal
transduction pathways initiated by that stimulus. In this
study, we have focused on signaling in response to insulin and
have shown that oxidation can serve as a molecular tag, which
allowed us to identify PTPs that play regulatory roles in the
insulin signaling pathway.
The importance of understanding the regulation of insulin
signaling is emphasized by the current prevalence of diabetes
and obesity in western society (42). A defect in post-insulin
receptor signaling is thought to be the basis of insulin resist-
ance in type II diabetes, and abnormal function of PTPs that
control the phosphorylation of the insulin receptor -subunit
and/or its substrates may contribute to the disease (43). Con-
sequently, there is excitement in the pharmaceutical industry
regarding the potential for development of PTP inhibitors as a
novel therapeutic strategy for treatment of type II diabetes. For
such a strategy to succeed, it is important to understand which
PTPs are the relevant regulators of insulin signaling. A variety
of studies have indicated that the phosphorylation of the insu-
lin receptor -subunit may be regulated by multiple PTPs,
depending upon the cellular context (43). Most prominent
among these is PTP1B, which has been implicated in the down-
regulation of insulin signaling by a variety of approaches, in-
cluding the phenotype of the PTP1B knock-out mouse (44, 45).
This and the identification of this phosphatase as a regulator of
signaling in response to cytokines such as leptin (46–48) have
led to considerable attention being focused on PTP1B as a
target for development of novel therapeutics for treatment of
both diabetes and obesity (49, 50). In our analysis, we observed
that insulin stimulation induced the rapid and transient oxi-
dation and inactivation of PTP1B. This observation, which
identified a PTP that is a known regulator of insulin signaling
as a target for reversible oxidation, provides validation for our
strategy. A similar observation has been reported by Mahadev
et al. (21), who went on to show that the Nox homolog, Nox 4,
is a regulator of PTP1B in this context (51).
Our study also identified TC45, a spliced variant of TC-PTP,
as a second PTP that is subject to insulin-induced, reversible
oxidation and inactivation. The two alternatively spliced forms
of TC-PTP share the same catalytic domain but differ at their
extreme C termini (52). The C terminus of TC48, similar to
PTP1B, is hydrophobic in nature and directs the protein to the
endoplasmic reticulum. Our data do not rule out the possible
involvement of TC48 in regulating insulin signal transduction;
however, this spliced variant displays a more restricted expres-
sion pattern than TC45 (52). TC45, which is characterized by
the presence of a bipartite nuclear localization signal, is rapidly
translocated from the nucleus to the cytoplasm after epidermal
growth factor stimulation, where it dephosphorylates the epi-
dermal growth factor receptor, as well as downstream adapters
including p52Shc, at the plasma membrane, thereby regulating
growth factor signaling (53, 54). Our observation of insulin-
induced oxidation and inactivation of TC45 suggests that this
PTP may also function as a negative regulator of insulin sig-
naling. Ablation of TC45 expression by RNAi led to enhanced
and sustained activation of PKB/AKT in response to insulin,
consistent with removal of an inhibitory constraint on the
signaling pathway. This suggests that, at least in Rat-1 and
HepG2 cells, both PTP1B and TC45 function in down-regula-
tion of the signaling response to insulin. Furthermore, in a
parallel study, it was shown that in immortalized fibroblasts
derived from TC-PTP / mice the signaling response to insu-
lin was enhanced compared with control TC-PTP / fibro-
FIG. 6. Ablation of TC45 by RNAi did not enhance the activa-
tion of PKB in response to PDGF in Rat-1 cells. Rat-1 cells were
left untransfected (Control) or transfected (siRNA) with 100 nM
siRNA oligonucleotide to TC45 (TCPTP1). Two days after transfection,
cells were deprived of serum for 16 h and then stimulated with 50 ng/ml
of PDGF for the indicated times. The immunoprecipitated (IP)
PDGFR- and total lysates (30 g) were immunoblotted with antibodies
to phosphotyrosine (G104 (60)), PDGFR- (958, Santa Cruz), phospho-
PKB, PKB, or TC45 (1910H) as indicated. Similar results were observed
in two independent experiments.
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blasts, consistent with our data and the conclusion that, in-
deed, insulin receptor signaling is regulated by TC-PTP (55).
Our data also address the issue of specificity in the role of
PTPs as regulators of signal transduction. Ablation of TC45 by
RNAi led to enhanced tyrosine phosphorylation of the insulin
receptor -subunit. Furthermore, the use of antibodies that
FIG. 7. Tyrosine phosphorylated IR--subunit is a substrate of TC45 in vivo. A, HepG2 cells overexpressing wild-type (WT) or trapping
mutant (DA) forms of PTP1B and TC45 were either left untreated (INS) or stimulated with 10 nM insulin for 5 min (INS) and then lysed in
substrate-trapping lysis buffer. Aliquots (1 mg) of cell lysate were incubated with anti-PTP1B antibody (FG6) or anti-TC45 antibody (CF4), as
indicated. The immunocomplexes were washed with lysis buffer, subjected to SDS-PAGE, and then immunoblotted with anti-IR- (C-19) antibody
(top panel). An aliquot of lysate (30 g) was immunoblotted with anti-PTP1B antibody (FG6) or anti-TC-PTP antibody (CF4) to verify PTP
expression (bottom panel). Data shown are representative of three independent experiments. B, serum starved, untransfected (Control), or TC45
siRNA (100 nM) transfected (siRNA) HepG2 cells were stimulated with 10 nM insulin for the indicated times. The insulin receptor was
immunoprecipitated from 750 g of cell lysate with anti-IR- antibody 29B4 and immunoblotted with anti-phosphotyrosine, anti-pY972-IR-
(BIOSOURCE), anti-pYpY1162/1163-IR-, and anti-IR- (C-19) antibodies (left panel). The right panel illustrates densitometric analyses of the gel
image to show the ratio of phosphorylated IR- relative to total IR- for total phosphotyrosine (upper), phosphorylation of Tyr-972 (middle), and
phosphorylation of the activation loop tyrosines 1162 and 1163 (lower). Similar results were observed in two independent experiments. A.U.,
arbitrary unit.
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recognize specific phosphorylation sites within the insulin re-
ceptor -subunit revealed that TC45 has the potential to show
preferential recognition of particular phosphorylation sites.
This is an important point for the PTP field, adding to the
change in the perception of these enzymes from that of playing
a housekeeping role to the current view of PTPs as specific
regulators of signaling, displaying specificity not only for par-
ticular proteins as substrates but also showing preferential
recognition of particular sites within those proteins. We report
in this study that ablation of TC45 led to enhanced phospho-
rylation of Tyr-972 in the insulin receptor -subunit, with little
or no effect on Tyr-1162 and Tyr-1163 of the activation loop
during the time course that was examined. Tyr-972 is an im-
portant residue for the recruitment of IRS-1 and Shc and the
activation of phosphatidylinositol 3-kinase (33), consistent
with the observation that dephosphorylation of the insulin
receptor -subunit by TC45 leads to inactivation of PKB/AKT
after insulin stimulation. It has been shown that PKB/AKT is
an important downstream effector of various receptor protein
tyrosine kinases through the activation of phosphatidylinositol
3-kinases (56). Therefore, we addressed further the issue of
specificity of TC45 in regulating signal transduction pathways
by testing its effects on PDGF signaling. Our results showed
that the ablation of endogenous TC45 by RNAi, conditions that
augmented tyrosine phosphorylation of the insulin receptor
-subunit as well as PKB/AKT signaling in response to insulin,
did not alter PDGF-induced autophosphorylation of PDGFR-
or activation of PKB/AKT. Interestingly, PDGF stimulation
does not lead to oxidation of TC-PTP. In contrast, PDGF in-
duced the transient oxidation and inactivation of a distinct
PTP, SHP-2 (19). Our observation is consistent with reports
that the ablation of TC-PTP by gene knock-out did not affect
either activation of extracellular signal-regulated kinase/mito-
gen-activated protein kinase or activation of PKB/AKT in re-
sponse to PDGF stimulation (57, 58). These data provide evi-
dence that TC45 neither recognizes all receptor protein
tyrosine kinases as substrates in vivo nor regulates all PKB/
AKT-dependent signaling but rather exerts specificity in its
effects as a regulator of signal transduction.
Now that the composition of enzyme families can be defined,
based upon the sequence of the human genome, the task at
hand is to establish the physiological function of the constitu-
ents of the human proteome. Although the importance of PTPs
in the regulation of signal transduction is becoming apparent,
the regulatory links between particular PTPs and specific sig-
naling pathways largely remain to be defined. This study illus-
trates that ligand-induced oxidation, which is required for op-
timal tyrosine phosphorylation, can be harnessed as a strategy
for “tagging” the PTPs that are critical regulators of the sig-
naling response to that ligand. The operating principle is that
the agonist (hormone, growth factor, and others) may enhance
tyrosine phosphorylation directly, by activation of a protein
tyrosine kinase, and/or indirectly, by inactivation of a PTP.
Thus, one function of ROS produced after agonist stimulation is
to inactivate transiently the PTP that provides the inhibitory
constraint upon the system, thus facilitating the initiation of
the signaling response (Fig. 8). Treatment of cells with H2O2
induced the oxidation of multiple PTPs (19), suggesting that
the family as a whole will be susceptible to this mode of regu-
lation. Since many and diverse stimuli have been shown to
trigger both tyrosine phosphorylation and ROS production, we
anticipate that this strategy may be applied broadly across the
PTP family. Upon identification, the use of substrate-trapping
and RNAi technologies should generate new insights into the
role of the PTP in control of signal transduction under normal
and pathophysiological conditions.
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